About Aquila Bioscience
Aquila Bioscience is a company based in Galway (Ireland) founded in 2012 by Afshin Samali and Lokesh Joshi. Aquila Bioscience offers products and services including AB Decontamination Device and ProShield Mask Spray. Aquila Bioscience operates in a competitive market with competitors including Anabios, Clyde Biosciences, Metrion Biosciences, Quiver Bioscience and Zen-Bio, among others.
- Headquarter Galway, Ireland
- Founders Afshin Samali, Lokesh Joshi
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$51.13 K (USD), Grant
Jul 31, 2022
-
Investors
European Union
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aquila Bioscience
Aquila Bioscience offers a comprehensive portfolio of products and services, including AB Decontamination Device and ProShield Mask Spray.
Wipe that captures and removes pathogens from skin surfaces
Spray enhancing cloth masks against pathogens without chemicals
Funding Insights of Aquila Bioscience
Investors in Aquila Bioscience
Aquila Bioscience has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked |
Investor details for Aquila Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aquila Bioscience
Investment portfolio details for Aquila Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aquila Bioscience
Detailed financials for Aquila Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aquila Bioscience Comparisons
Peer comparison for Aquila Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aquila Bioscience
Aquila Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Anabios, Clyde Biosciences, Metrion Biosciences, Quiver Bioscience and Zen-Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Ex-vivo human tissue studies are performed for preclinical drug discovery.
|
|
| Locked | Locked | Locked |
Cardiac safety testing is conducted using iPS-derived heart cells.
|
|
| Locked | Locked | Locked |
Ion channel screening and cardiac safety profiling services are provided.
|
|
| Locked | Locked | Locked |
Developer of transformational medicines for neurological disorders
|
|
| Locked | Locked | Locked |
Cell-based solutions are provided to accelerate therapy discovery and development.
|
|
| Locked | Locked | Locked |
Multiplexed immunoassays for protein biomarkers are developed via proprietary platform.
|
Detailed competitors of Aquila Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aquila Bioscience
Complete news archive for Aquila Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aquila Bioscience
Aquila Bioscience was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Aquila Bioscience is headquartered in Galway, Ireland.
Aquila Bioscience is a spin-out company from the National University of Ireland Galway. It offers cell-based assays to support preclinical research. The company also focuses on glycoscience(polysaccharides) research to treat cell stress in chronic and infectious diseases. The cell-based services it offers are toxicity assays, proliferation assays, immunomodulation assays, gene expression studies, reporter gene studies, custom assay development. The company is also engaged in developing products and services for enivronmental sensing applications.
Aquila Bioscience's top competitors include Metrion Biosciences, Quiver Bioscience and Anabios.
Aquila Bioscience offers AB Decontamination Device and ProShield Mask Spray.
Aquila Bioscience has 2 investors. Key investors include European Union, and EIC Fund.